Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 symbols : PFE save search
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.03%
H: 0.18%
C: -0.88%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.49%
H: 0.2%
C: -1.33%
covid-19 fda vaccine approval
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
Published: 2023-05-25 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -1.77%
covid-19 fda approval risk
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Published: 2022-12-09 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
covid-19 fda designation candidate vaccine influenza fast track designation
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Published: 2022-12-08 (Crawled : 16:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -0.76%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.12%
H: 3.36%
C: 3.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.37%
H: 5.31%
C: 5.26%
covid-19 fda children vaccine authorization
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
Published: 2022-11-10 (Crawled : 15:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.15%
H: 4.22%
C: 4.22%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.72%
H: 0.47%
C: -0.31%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -4.59%
H: 3.28%
C: 3.06%
covid-19 chmp children vaccine positive
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Published: 2022-11-04 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 4.93%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.93%
H: 0.15%
C: -0.53%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 7.6%
H: 0.33%
C: -1.27%
covid-19 vaccine response
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Published: 2022-10-12 (Crawled : 15:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.41%
H: 2.49%
C: -0.14%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 3.4%
H: 4.91%
C: 2.06%
covid-19 fda children vaccine authorization
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Published: 2022-09-01 (Crawled : 14:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.51%
H: 1.07%
C: 1.07%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.2%
H: 3.35%
C: 3.3%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.04%
H: 0.45%
C: 0.05%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.68%
H: 1.61%
C: 1.5%
covid-19 chmp vaccine positive
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Published: 2022-08-31 (Crawled : 14:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.75%
H: 1.98%
C: 1.98%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.35%
H: 0.6%
C: -1.7%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.63%
H: 1.42%
C: -2.27%
covid-19 fda vaccine granted authorization
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Published: 2022-08-23 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -0.87%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.98%
H: 0.21%
C: -0.85%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.13%
H: 1.14%
C: -0.84%
covid-19 children vaccine
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Published: 2022-08-22 (Crawled : 15:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.12%
H: 0.38%
C: -0.63%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.79%
H: 2.56%
C: 1.06%
covid-19 fda vaccine application authorization
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.69%
H: 0.61%
C: 0.02%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.28%
covid-19 candidate vaccine study
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Published: 2022-06-29 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 1.06%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.79%
H: 2.31%
C: 1.43%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -4.58%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 3.2%
H: 4.97%
C: 1.76%
covid-19 vaccine agreement
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
covid-19 vaccine response
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Published: 2022-06-17 (Crawled : 14:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -4.49%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.76%
H: 5.75%
C: 5.5%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
covid-19 fda children vaccine authorization emergency use authorization
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.12%
H: 0.99%
C: 0.13%
covid-19 treatment
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Published: 2022-05-23 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 2.55%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.85%
H: 0.06%
C: -1.91%
covid-19 children vaccine
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.